Holen Sie sich die Stockscreener-App
0.00
100.00%
-135.07
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Therapeutics Market Sentiment - Benzinga España
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighShould You Buy? - MarketBeat
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal - TradingView
What Will Apogee Therapeutics (NASDAQ:APGE) Say on Trials? - Kalkine Media
Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO Dambkowski sells $737k in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $737k in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liquidity Mapping Around (APGE) Price Events - news.stocktradersdaily.com
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Truist Financial Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Raises Target Price to $135 - Moomoo
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
Apogee Therapeutics Director Vote: My Take On The 8-K Liga Mx (YjhKcvC1lD) - Mshale
Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research - MarketBeat
APGE Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
BTIG Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal By Investing.com - Investing.com South Africa
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal - Investing.com Nigeria
APOGEE THERAPEUTICS, INC. : BTIG CUTS TO NEUTRAL FROM BUY - Bitget
Apogee Therapeutics Directors Execute Stock Options, Increasing Holdings - Kalkine Media
Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options - Stock Titan
Apogee Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com
Apogee Therapeutics,Q2 2026 Net Loss $85.9 - Moomoo
My Takeaway On Apogee Therapeutics' Massive Cash Raise Humberto Cruz (GVA0ZiS739) - Mshale
Apogee Therapeutics, Inc. (APGE): An Insightful Stock Analysis on Growth Potential and Market Position - DirectorsTalk Interviews
APGE SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Apogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine Media
Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary - TradingView
Apogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS - MarketBeat
Apogee Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q2 Net Loss $85.9M, vs. FactSet Est of $78.7M Loss - marketscreener.com
Apogee reports $85.9 million Q2 loss as AbbVie deal advances - Quiver Quantitative
Apogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingView
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates - The Manila Times
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results - Quiver Quantitative
Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75 - Stock Titan
Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE - MarketBeat
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares By Investing.com - Investing.com India
Apogee Therapeutics CMO Carl Dambkowski disposes of USD 737,935 in common shares - Bitget
Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan - Stock Titan
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics stock hits all-time high at 134.47 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock hits all-time high at 134.47 USD - Investing.com
APGE, Apogee Therapeutics, Inc., 2025-03-11, Stock Prices And MACD Indicators #MACD #APGE Al Nassr (6zlIIYGDqA) - Mshale
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighWhat's Next? - MarketBeat
First Trust Advisors LP Grows Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics Inc. $APGE Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout - Yahoo Finance
AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal - Bloomberg.com
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Navigating the Biotech Landscape with a $10 Billion Market Cap - DirectorsTalk Interviews
Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain? - Yahoo Finance
Apogee Therapeutics (APGE) to Post Quarterly Earnings on Monday - marketbeat.com
Weekly Recap: APGE sale probe and zumilokibart efficacy - TradingView
Perceptive Advisors LLC Has $129.65 Million Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics, Inc. Revenue Breakdown – NASDAQ:APGE - TradingView
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates - Reuters
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):